Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
VS
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
View stock

Stock highlights

Stock comparison highlights
Stock name
FreseniusAbbVie
Last price
€45.22$284.80
Currency
EUR
USD
€25B$511B
16.4481.67
€2.71$3.54
0.830.28
€1.05$6.83
2.36%2.39%
Sector
HealthHealth
Employees
178,48657,000
Ticker
€FRE$ABBV
Primary listing
XETRANYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in €FRE or $ABBV on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.